# A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

> **NCT04908202** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 670 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Deucravacitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04908202
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-13
- **Primary completion:** 2024-09-05
- **Final completion:** 2027-06-10
- **Target enrollment:** 670 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908202, "A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04908202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*